Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1-2 years in children with Hurler or Hunter syndrome
Lynda E Polgreen et al. Mol Genet Metab. 2014 Feb.
Abstract
Patients with Hurler or Hunter syndrome typically have moderate to severe growth deficiencies despite therapy with allogeneic hematopoietic stem cell transplantation and/or enzyme replacement therapy. It is unknown whether treatment with recombinant human growth hormone (hGH) can improve growth in these children. The objectives of this study were to determine the effects of hGH on growth, bone mineral density (BMD), and body composition in children with Hurler or Hunter syndrome enrolled in a longitudinal observational study. The difference in annual change in outcomes between hGH treated and untreated subjects was estimated by longitudinal regression models that adjusted for age, Tanner stage, and sex where appropriate. We report on 23 participants who completed at least 2 annual study visits (10 [43%] treated with hGH): Hurler syndrome (n=13) average age of 9.8 ± 3.1 years (range 5.3-13.6 years; 54% female) and Hunter syndrome (n=10) average age of 12.0 ± 2.7 years (range 7.0-17.0 years; 0% female). As a group, children with Hurler or Hunter syndrome treated with hGH had no difference in annual change in height (growth velocity) compared to those untreated with hGH. Growth velocity in hGH treated individuals ranged from -0.4 to 8.1cm/year and from 0.3 to 6.6 cm/year in the untreated individuals. Among children with Hunter syndrome, 100% (N=4) of those treated but only 50% of those untreated with hGH had an annual increase in height standard deviation score (SDS). Of the individuals treated with hGH, those with GHD had a trend towards higher annualized growth velocity compared to those without GHD (6.5 ± 1.9 cm/year vs. 3.5 ± 2.1cm/year; p=.050). Children treated with hGH had greater annual gains in BMD and lean body mass. In conclusion, although as a group we found no significant difference in growth between individuals treated versus not treated with hGH, individual response was highly variable and we are unable to predict who will respond to treatment. Thus, a trial of hGH may be appropriate in children with Hurler or Hunter syndrome, severe short stature, and growth failure. However, efficacy of hGH therapy should be evaluated after 1 year and discontinued if there is no increase in growth velocity or height SDS. Finally, the long-term benefits of changes in body composition with hGH treatment in this population are unknown.
Keywords: BMD; BMI; Body composition; CSF; ERT; GAG; GHD; Growth; Growth hormone; HCT; Hunter syndrome; Hurler syndrome; IH; LBM; MPS; Mucopolysaccharidosis; SCFE; SDS; SGA; TBI; body mass index; bone mineral density; central spinal fluid; enzyme replacement therapy; glycosaminoglycan; growth hormone deficiency; hGH; hematopoietic stem cell transplantation; intracranial hypertension; lean body mass; mucopolysaccharidosis; recombinant human growth hormone; slipped capital femoral epiphysis; small for gestational age; standard deviation score; total body irradiation.
Copyright © 2013 Elsevier Inc. All rights reserved.
PubMed Disclaimer
Conflict of interest statement
Conflicts of interest: WT and PO have no conflicts of interest.
Figures Fig. 1
Change in height by gender for hGH treated (solid line) vs. not treated (dashed line) with Hurler syndrome and Hunter syndrome plotted on CDC 2000 growth charts.
References
Whitley CB. McKusick's Heritable Disorders of Connective Tissue. Mosby; St. Louis: 1993. The mucopolysaccharidoses; pp. 367–500.
Neufeld E. The Metabolic and Molecular Basis of Inherited Disease. McGraw-Hill; New York: 2001. The Mucopolysaccharidoses; pp. 3421–3452.
Polgreen LE, Tolar J, Plog M, Himes JH, Orchard PJ, Whitley CB, et al. Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41:1005–11. - PubMed
Gardner CJ, Robinson N, Meadows T, Wynn R, Will A, Mercer J, et al. Growth, final height and endocrine sequelae in a UK population of patients with Hurler syndrome (MPS1H) J Inherit Metab Dis. n.d;34:489–97. - PubMed
Jones SA, Parini R, Harmatz P, Giugliani R, Fang J, Mendelsohn NJ. The effect of idursulfase on growth in patients with Hunter syndrome: Data from the Hunter Outcome Survey (HOS) Mol Genet Metab. 2013 - PubMed
Grants and funding
U54 NS065768/NS/NINDS NIH HHS/United States K23 AR057789/AR/NIAMS NIH HHS/United States UL1 TR000114/TR/NCATS NIH HHS/United States K23AR057789/AR/NIAMS NIH HHS/United States U54NS065768/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Elsevier Science Europe PMC PubMed Central
Other Literature Sources
scite Smart Citations
Medical
ClinicalTrials.gov MedlinePlus Health Information
Molecular Biology Databases
NIAID Data Ecosystem - Find datasets on Infectious and Immune-mediated Diseases